Abstract
Prostate cancer (PCa) is the second most common type of cancer in the world and the fifth highest cause of cancer-related deaths in men [1], with the highest prevalence in the United States and Western Europe. The current diagnostic gold standards are controversial and typically lead to over-diagnosis [2]. Blood tests are commonly used to check the level of the prostate specific antigen (PSA), when in fact this antigen is organ-specific but not cancer-specific. Lack of clarity over diagnosis as well as prognosis leads to large numbers of unnecessary treatments, which are highly invasive and with a range of unpleasant side effects. New methods are therefore required to improve the existing clinical outcomes at both the diagnostic and the prognostic level.
© 2017 IEEE
PDF ArticleMore Like This
Yuri Belotti, Michael Conneely, Tianjun Huang, Stephen McKenna, Ghulam Nabi, and David McGloin
1041305 European Conference on Biomedical Optics (ECBO) 2017
Ammasi Periasamy, Shagufta R. Alam, Zdenek Svindrych, and Horst Wallrabe
1041402 European Conference on Biomedical Optics (ECBO) 2017
S.J. van Breugel, I. Low, M.L. Christie, M.R. Pokorny, H.U. Holtkamp, M.K. Nieuwoudt, M.C. Simpson, K. Zargar-Shoshtari, and C. Aguergaray
cl_p_2 The European Conference on Lasers and Electro-Optics (CLEO/Europe) 2023